Skip to main content
Top
Published in: Archives of Virology 12/2011

01-12-2011 | Original Article

Complete genome sequences and phylogenetic analysis of hepatitis delta viruses isolated from nine Turkish patients

Authors: İnci Çelik, Ersin Karataylı, Emrah Çevik, S. Gökçe Kabakçı, Senem Ceren Karataylı, Bedia Dinç, Kubilay Çınar, Kendal Yalçın, Ramazan İdilman, Cihan Yurdaydın, A. Mithat Bozdayi

Published in: Archives of Virology | Issue 12/2011

Login to get access

Abstract

Hepatitis delta virus (HDV) is a subviral agent of hepatitis B virus (HBV), and its life cycle is dependent on HBV. It is commonly accepted that HDV has eight distinct genotypes. In this study, the complete nucleotide sequences of HDV genomes isolated from nine Turkish patients were obtained by RT-PCR using two pairs of primers that cover the entire HDV genome. PCR products were sequenced directly. The results showed that these 9 isolates were approximately 1680 base pairs in length and clustered in the genotype HDV-1 branch when phylogenetic analysis was done with the sequences together with the complete sequences of HDV genomes representing each genotype retrieved from GenBank. Analysis of a portion of the large hepatitis D antigen (L-HDAg) gene showed that sequence similarity among these Turkish isolates is between 87.4 and 97.1%, and the Turkish isolates have the most sequence similarity to HDV-1 (90.5%), while they have the least sequence similarity to HDV-3 (64.1%). Full-genome analysis indicates that the sequence similarity is between 80.7 and 95.4%, and the highest sequence similarity is 84.8% (between the Turkish isolates and HDV-1). The lowest sequence similarity is 56.4% (between the Turkish isolates and HDV-3). In conclusion, phylogenetic analysis shows that the Turkish HDV isolates belong to HDV-1.
Literature
1.
go back to reference Rizzetto M, Canese MG, Arico S, Crivelli O, Trepo C, Bonino F, Verme G (1977) Immunofluorescence detection of new antigen-antibody system (d/anti-d) associated to hepatitis B virus in liver and in serum of HbsAg carriers. Gut 18:997–1003PubMedCrossRef Rizzetto M, Canese MG, Arico S, Crivelli O, Trepo C, Bonino F, Verme G (1977) Immunofluorescence detection of new antigen-antibody system (d/anti-d) associated to hepatitis B virus in liver and in serum of HbsAg carriers. Gut 18:997–1003PubMedCrossRef
3.
go back to reference Yurdaydin C, Bozkaya H, Idilman R, Bozdayi AM (2010) Natural history and treatment of CDH. J Viral Hepat 11:749–756CrossRef Yurdaydin C, Bozkaya H, Idilman R, Bozdayi AM (2010) Natural history and treatment of CDH. J Viral Hepat 11:749–756CrossRef
4.
go back to reference Wang KS, Choo QL, Weiner AJ, Ou JH, Najarian RC, Thayer RM, Mullenbach GT, Denniston KJ, Gerin JL, Houghton M (1986) Structure, sequence and expression of the hepatitis delta (delta) viral genome. Nature 323:508–514PubMedCrossRef Wang KS, Choo QL, Weiner AJ, Ou JH, Najarian RC, Thayer RM, Mullenbach GT, Denniston KJ, Gerin JL, Houghton M (1986) Structure, sequence and expression of the hepatitis delta (delta) viral genome. Nature 323:508–514PubMedCrossRef
5.
go back to reference Kuo MY, Sharmeen L, Dinter-Gottlieb G, Taylor J (1988) Characterization of self-cleaving RNA sequences on the genome and antigenome of human hepatitis delta virus. J Virol 62:4439–4444PubMed Kuo MY, Sharmeen L, Dinter-Gottlieb G, Taylor J (1988) Characterization of self-cleaving RNA sequences on the genome and antigenome of human hepatitis delta virus. J Virol 62:4439–4444PubMed
6.
go back to reference Taylor J, Mason W, Summers J, Goldberg J, Aldrich C, Coates L, Gerin J, Gowans E (1987) Replication of human hepatitis delta virus in primary cultures of woodchuck hepatocytes. J Virol 61:2891–2895PubMed Taylor J, Mason W, Summers J, Goldberg J, Aldrich C, Coates L, Gerin J, Gowans E (1987) Replication of human hepatitis delta virus in primary cultures of woodchuck hepatocytes. J Virol 61:2891–2895PubMed
7.
go back to reference Casey JL, Bergmann KF, Brown TL, Gerin JL (1992) Structural requirements for RNA editing in hepatitis delta virus: evidence for a uridine-to-cytidine editing mechanism. Proc Natl Acad Sci USA 89:7149–7153PubMedCrossRef Casey JL, Bergmann KF, Brown TL, Gerin JL (1992) Structural requirements for RNA editing in hepatitis delta virus: evidence for a uridine-to-cytidine editing mechanism. Proc Natl Acad Sci USA 89:7149–7153PubMedCrossRef
8.
go back to reference Zheng H, Fu TB, Lazinski D, Taylor J (1992) Editing on the genomic RNA of human hepatitis delta virus. J Virol 66:4693–4697PubMed Zheng H, Fu TB, Lazinski D, Taylor J (1992) Editing on the genomic RNA of human hepatitis delta virus. J Virol 66:4693–4697PubMed
9.
go back to reference Chang FL, Chen PJ, Tu SJ, Wang CJ, Chen DS (1991) The large form of hepatitis delta antigen is crucial for assembly of hepatitis delta virus. Proc Natl Acad Sci USA 88:8490–8494PubMedCrossRef Chang FL, Chen PJ, Tu SJ, Wang CJ, Chen DS (1991) The large form of hepatitis delta antigen is crucial for assembly of hepatitis delta virus. Proc Natl Acad Sci USA 88:8490–8494PubMedCrossRef
10.
go back to reference Rizzetto M, Hadziyannis S, Hansson BG, Toukan A, Gust I (1992) Hepatitis delta virus infection in the world: epidemiological patterns and clinical expression. Gastroenterol Int 5:18–32 Rizzetto M, Hadziyannis S, Hansson BG, Toukan A, Gust I (1992) Hepatitis delta virus infection in the world: epidemiological patterns and clinical expression. Gastroenterol Int 5:18–32
11.
go back to reference Wedemeyer H, Manns MP (2010) Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 7:31–40PubMedCrossRef Wedemeyer H, Manns MP (2010) Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 7:31–40PubMedCrossRef
12.
go back to reference Degertekin H, Yalcin K, Yakut M, Yurdaydin C (2008) Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver Int 28:494–498PubMedCrossRef Degertekin H, Yalcin K, Yakut M, Yurdaydin C (2008) Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver Int 28:494–498PubMedCrossRef
13.
go back to reference Wedemeyer H, Heidrich B, Manns MP (2007) Hepatitis D virus infection—not a vanishing disease in Europe. Hepatology 45:1331–1332PubMedCrossRef Wedemeyer H, Heidrich B, Manns MP (2007) Hepatitis D virus infection—not a vanishing disease in Europe. Hepatology 45:1331–1332PubMedCrossRef
14.
go back to reference Bozdayi AM, Aslan N, Bozdayi G, Turkyilmaz AR, Sengezer T, Wend U, Erkan O, Aydemir F, Zakirhodjaev S, Orucov S, Bozkaya H, Gerlich W, Karayalcin S, Yurdaydin C, Uzunalimoglu O (2004) Molecular epidemiology of hepatitis B, C, and D viruses in Turkish patients. Arch Virol 149:2115–2129PubMedCrossRef Bozdayi AM, Aslan N, Bozdayi G, Turkyilmaz AR, Sengezer T, Wend U, Erkan O, Aydemir F, Zakirhodjaev S, Orucov S, Bozkaya H, Gerlich W, Karayalcin S, Yurdaydin C, Uzunalimoglu O (2004) Molecular epidemiology of hepatitis B, C, and D viruses in Turkish patients. Arch Virol 149:2115–2129PubMedCrossRef
15.
go back to reference Altuglu I, Ozacar T, Sertoz RY, Erensoy S (2007) Hepatitis delta virus (HDV) genotypes in patients with chronic hepatitis: molecular epidemiology of HDV in Turkey. Int J Infect Dis 11:58–62PubMedCrossRef Altuglu I, Ozacar T, Sertoz RY, Erensoy S (2007) Hepatitis delta virus (HDV) genotypes in patients with chronic hepatitis: molecular epidemiology of HDV in Turkey. Int J Infect Dis 11:58–62PubMedCrossRef
16.
go back to reference Grazie AN, Smedile A, Andriulli A, Rizzetto M, Gerin JL, Casey JL (1997) The predominance of hepatitis delta virus genotype I among chronically infected Italian patients. Hepatology 25:728CrossRef Grazie AN, Smedile A, Andriulli A, Rizzetto M, Gerin JL, Casey JL (1997) The predominance of hepatitis delta virus genotype I among chronically infected Italian patients. Hepatology 25:728CrossRef
17.
go back to reference Casey JL, Brown TL, Colan EJ, Wignall FS, Gerin JL (1993) A genotype of hepatitis D virus that occurs in northern South America. Proc Natl Acad Sci USA 90:9016–9020PubMedCrossRef Casey JL, Brown TL, Colan EJ, Wignall FS, Gerin JL (1993) A genotype of hepatitis D virus that occurs in northern South America. Proc Natl Acad Sci USA 90:9016–9020PubMedCrossRef
18.
go back to reference Nakano T, Shapiro CN, Hadler SC, Casy JL, Mizokami M, Orito E, Robertson BH (2001) Characterization of hepatitis D virus genotype III among Yucpa Indians in Venezuela. Gen Virol 82:2183–2189 Nakano T, Shapiro CN, Hadler SC, Casy JL, Mizokami M, Orito E, Robertson BH (2001) Characterization of hepatitis D virus genotype III among Yucpa Indians in Venezuela. Gen Virol 82:2183–2189
19.
go back to reference Lee CZ, Chen PJ, Chen DS (1995) Large hepatitis delta antigen in packaging and replication inhibition: role of the carboxyl-terminal 19 amino acids and amino-terminal sequences. J Virol 69:5332–5336PubMed Lee CZ, Chen PJ, Chen DS (1995) Large hepatitis delta antigen in packaging and replication inhibition: role of the carboxyl-terminal 19 amino acids and amino-terminal sequences. J Virol 69:5332–5336PubMed
Metadata
Title
Complete genome sequences and phylogenetic analysis of hepatitis delta viruses isolated from nine Turkish patients
Authors
İnci Çelik
Ersin Karataylı
Emrah Çevik
S. Gökçe Kabakçı
Senem Ceren Karataylı
Bedia Dinç
Kubilay Çınar
Kendal Yalçın
Ramazan İdilman
Cihan Yurdaydın
A. Mithat Bozdayi
Publication date
01-12-2011
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 12/2011
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-011-1120-y

Other articles of this Issue 12/2011

Archives of Virology 12/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine